menu
    • menu
    [{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tecarfarin","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Boustead Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Boustead Securities"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tecarfarin","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ Boustead Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Boustead Securities"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tecarfarin","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cadrenal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tecarfarin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tecarfarin","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"The Sage Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Tecarfarin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ The Sage Group","highestDevelopmentStatusID":"9","companyTruncated":"Cadrenal Therapeutics \/ The Sage Group"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Tecarfarin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Tecarfarin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cadrenal Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Cadrenal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tecarfarin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cadrenal Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Cadrenal Therapeutics \/ H.C. Wainwright & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Cadrenal Therapeutics

    Menu

    Cadrenal Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $4.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

                            Details : The proceeds from the financing will be used to advance the company's lead development candidate, ATI-5923 (tecarfarin). It is designed to prevent heart attacks, and strokes.

                            Brand Name : ATI-5923

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 01, 2024

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $4.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

                            Details : The net proceeds will be used in developing ATI-5923 (tecarfarin), a new vitamin K antagonist (VKA), prepare for our pivotal Phase 3 trial.

                            Brand Name : ATI-5923

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 24, 2024

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Abbott Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cadrenal and Abbott Collaborate on Novel Anticoagulant Tecarfarin for LVAD Patients

                            Details : The collaboration aims to advance the novel anticoagulant ATI-5923 (tecarfarin), designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices.

                            Brand Name : ATI-5923

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 06, 2024

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Abbott Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin,Warfarin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : The Sage Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercializat...

                            Details : Under the partnership, Sage Group will assist Cadrenal in exploring strategic partnerships, co-development and licensing agreements for ATI-5923 (tecarfarin), a late-stage, novel, oral and reversible anticoagulant designed to prevent heart attacks, strok...

                            Brand Name : ATI-5923

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 12, 2023

                            Lead Product(s) : Tecarfarin,Warfarin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : The Sage Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

                            Details : Tecarfarin is an vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin, which is investigated for the treatment of patients with antiphospholipid syndrome (APS) who require chronic anticoagulation.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2023

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseas...

                            Details : Tecarfarin is an vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin, which is investigated for the treatment of implanted medical devices for heart diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 01, 2023

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Boustead Securities

                            Deal Size : $7.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering

                            Details : The Company intends to use the net proceeds in developing tecarfarin, a novel cardiorenal therapy for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heart...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Boustead Securities

                            Deal Size : $7.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Syste...

                            Details : Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 23, 2023

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Cadrenal Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Boustead Securities

                            Deal Size : $7.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)

                            Details : The net proceeds will be used for developing tecarfarin, a novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 20, 2023

                            Lead Product(s) : Tecarfarin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Boustead Securities

                            Deal Size : $7.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth